查詢結果分析
相關文獻
- 核醫藥物放射性核種治療製劑錸-188--錫-1,1氫氧亞乙基二磷酸鹽之特性研究
- 放射性同位素治療劑錸-188-錫-1,1-羥基亞乙基二磷酸鹽之體外特性分析與生物體分佈研究
- Clodronate--治療乳癌的骨轉移
- 骨骼轉移的單次與分次緩和性放射治療的比較:一個前瞻性隨機試驗
- 照顧一位肺癌骨轉移之年輕女病患之護理經驗
- 癌症病人的骨轉移
- Breast Cancer Metastasis Causing Bilateral Subtrochanteric Pathological Fractures: A Case Report
- 癌症併發骨轉移的機制
- 從「見骨頭」到「健骨頭」:淺談核醫在癌症骨轉移的應用
- Denosumab治療骨鬆與腫瘤骨轉移
頁籤選單縮合
題名 | 核醫藥物放射性核種治療製劑錸-188--錫-1,1氫氧亞乙基二磷酸鹽之特性研究=The Study of Characterizations of Rhenium-188-Sn-1,1-Hydroxy Ethylidene Diphosphonate in Radionuclide Therapy for Nuclear Medicine |
---|---|
作者 | 丁慧枝; 曾誠齊; 丁幹; 謝柏蒼; 黃英峰; 李全孝; 劉怡慶; | 書刊名 | 放射治療與腫瘤學 |
卷期 | 6:2 1999.06[民88.06] |
頁次 | 頁105-112 |
分類號 | 418.346 |
關鍵詞 | 放射核種治療製劑; 骨轉移; Radionuclide therapy; Rhenium-188-sn-1,1-hydroxy ethylidene diphosphonate; Bone metastasis; |
語文 | 中文(Chinese) |
中文摘要 | 目的:本研究欲深入研究核醫藥物放射核種治療製劑錸-188--錫-1,1-氫氧亞乙 基二磷酸鹽(Re-188-HEDP)之特性。 材料與方法:核種產生器Re-188孳生器是核能研究所同位素組與國際間合作由美國Oak Ridge National Laboratory提供。首先進行Re-188-Uigand錯合物之合成及鑑定,並進行 Re-188-Uigand製劑中形成之錯化合物成份分析,並探討製劑中配位子(ligand)、還原劑 (SnCl��.2H��0)、抗氧化劑(gentisic acid)及pH值大小等因素對錯化合物各成份含 量之影響。其次Re-188-Sn-HEDP在各條件下製備之配劑在體外(in vitro)進行特性測定、 包含與血中蛋白質的鍵結量及辛醇╱緩衝液(l-octanol/buffer solution)之分占係數之 測定,並進行R-188-Ligand錯化合物製劑之生物分佈測定。 結果:由實驗結果發現放射性核種治療製劑錸酸鹽R-188-Sn-HEDP配劑使用TSK G2000 PW size exclusion gel管柱分析可得五個主成份電荷範圍在-1至-3之間,使用Amine A28陰 離子交換樹酯管柱分析可得五個主成份電荷範圍在-3至-12之間。當配劑條件改變時放射性 核種治療製劑錸酸鹽Re-188-Sn-HEDP主要成份亦有很大的變化。富pH值高於11以上主成 份幾乎只呈現一種主成份,pH值愈低酸性愈強時配劑中主成份就有愈多種。 結論:因此pH降低可分離出置留時間比較長的主成份出來。至於配位子在配劑中對主成份 之影響本研究發現配位子HEDP與還原劑SnCl��2H��0之比例值不同時主成份之含量也會 不同。 |
英文摘要 | Objective: The goal of this study was to analysis and characterize the agent of rhenium-188-Sn-1,1-hydroxyethylidene diphosphonate in radionuclide therapy for Nuclear Medicine. Materials and Methods: We use the generator ofW-188/Re-188 to do some research, because we cooperated with researchers of Institute of Nuclear Energy Research. There are the generators of W-188/Re-188 from Oak Ridge National Laboratory in U.S.A.. First, We synthesize and identify the rhenium-186-1,1-hydroxyethylidene diphosphonate in different condition, then to analyte (including in different con- ditions) and proceed the biodistribution of the agent of rhenium-188-Sn-1,1- hydroxyethylidene diphosphonate. Results and Discussions: In this study, we found that the main components were five peaks by the analytical method of TSK G2000 PW size exclusion gel in HPLC and their charge is between -1 and -3. The same main components are five peaks by the analytical method of Amine A28 in HPLC and their charge is between -3 and -12 in different proportions. Conclusion: We found that the component was only one in the high pH of the rhenium-188-Sn-1,1-hydroxyethylidene diphosphonate, and the components increased more and more when the concentration of hydrogen ion increased. The contents of the components are also dependent on the ratio of the ligand and reduced agent. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。